Opinion|Videos|October 14, 2024
Real-World Data on Luspatercept in LR-MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, reviews real-world data on luspatercept, discussing treatment patterns and outcomes, including transfusion burden, hemoglobin increase, and other key baseline data that may differ from registrational studies in the context of managing lower-risk myelodysplastic syndromes (LR-MDS).
Advertisement
Episodes in this series
Video content above is prompted by the following:
Now that luspatercept has been available for a while, we have real-world data reports.
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
The designation expands the investigational immunotherapy’s development across tumor types for patients whose disease progresses after prior treatment, including immune checkpoint inhibition.
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Durability of PFS and OS Benefit vs. Historical Control
5